Academic Journals Database
Disseminating quality controlled scientific knowledge

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Author(s): Ibeas P | Cantos B | Provencio M.

Journal: Blood and Lymphatic Cancer : Targets and Therapy
ISSN 1179-9889

Volume: 2011;
Issue: default;
Start page: 19;
Date: 2011;
Original page

Patricia Ibeas, Blanca Cantos, Mariano ProvencioClinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, SpainAbstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.Keywords: everolimus, positron emission tomography, chemotherapy
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Rapperswil
Tango Rapperswil